Asset Details
Do you wish to reserve the book?
The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases
Do you wish to request the book?
The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases
2018
Overview
Background
The Immunoscore was initially established to evaluate the prognosis of stage I/II/III colorectal cancer patients. However, the feasibility of the Immunoscore for the prognosis of colorectal cancer liver metastases (CRCLM) has not been reported.
Methods
Liver metastases in 249 CRCLM patients were retrospectively analyzed. The Immunoscore was assessed according to the counts and densities of CD3+ and CD8+ T cells in the central- and peritumoral areas by immunohistochemistry. The prognostic role of the Immunoscore for relapse–free survival (RFS) and overall survival (OS) was analyzed with Kaplan–Meier curves and Cox multivariate models, and confirmed via an internal validation. Receiver operating characteristic (ROC) curves were plotted to compare the prognostic values of the Immunoscore and the clinical risk score (CRS) system.
Results
CRCLM patients with high Immunoscores (> 2) had significantly longer RFS [median RFS (95% confidence interval; 95% CI) 21.4 (7.8–35.1) vs. 8.7 (6.8–10.5) months,
P
< 0.001] and OS [median OS (95% CI): not reached vs. 28.7 (23.2–34.2) months,
P
< 0.001] than those with low Immunoscores (≤ 2). After stratification by CRS, the Immunoscore retained a statistically significant prognostic value for OS. The areas under the ROC curves (AUROCs) of the Immunoscore and the CRS system for RFS were 0.711 [95% CI 0.642–0.781] and 0.675[95% CI 0.601–0.749] (
P
= 0.492), whereas the AUROC of the Immunoscore system for OS was larger than that of the CRS system [0.759 (95% CI 0.699–0.818) vs. 0.660 (95% CI 0.592–0.727);
P
= 0.029].
Conclusions
The Immunoscore of liver metastases can be applied to predict the prognosis of CRCLM patients following liver resection.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Cancer
/ CD8-Positive T-Lymphocytes - metabolism
/ CD8-Positive T-Lymphocytes - pathology
/ Colorectal Neoplasms - metabolism
/ Colorectal Neoplasms - pathology
/ Female
/ Humans
/ Liver
/ Liver Neoplasms - metabolism
/ Lymphocytes, Tumor-Infiltrating - metabolism
/ Lymphocytes, Tumor-Infiltrating - pathology
/ Male
/ Medicine
/ Neoplasm Recurrence, Local - metabolism
/ Neoplasm Recurrence, Local - pathology
/ Oncology
/ Original
/ Survival
